Diosbulbin B

Diosbulbin B, a diterpene lactone, is an anticancer agent. Diosbulbin B is an orally active component of Dioscorea. bulbifera L. Diosbulbin B can inhibit cell proliferation, induce G0/G1 phase arrest and apoptosis. Diosbulbin B can induce autophagy and mitochondrial dysfunction. Diosbulbin B can induce liver injury. Diosbulbin B can be used for the research of cancer, such as non-small cell lung cancer (NSCLC)^[1][2][3]. In Vitro: Diosbulbin B (0.5-400 μM, 24-72 h) inhibits proliferation in A549 and PC-9 cells, with IC₅₀ values of 44.61 and 22.78 μM, respectively^[1].
Diosbulbin B (12.5-100 μM, 24 h) enhances the ratio of cells in the G0/G1 phase in A549 and PC-9 cells^[1].
Diosbulbin B (12.5-100 μM, 48 h) induces apoptosis in A549 and PC-9 cells^[1].
Diosbulbin B (12.5-100 μM, 48 h) inhibits colony formation in A549 and PC-9 cells^[1].
Diosbulbin B (12.5-100 μM, 48 h) reduces the levels of YY1 and apoptosis-related proteins and increases p53 levels in A549 and PC-9 cells^[1].
Diosbulbin B (50-200 μM, 48h) induces autophagy and apoptosis in L-02 hepatocytes^[3].
Diosbulbin B (50-200 μM, 48 h) causes mitochondrial dysfunction in L-02 hepatocytes^[3].
In Vivo: Diosbulbin B (5-15 mg/kg, i.p., daily for 2 weeks) inhibits tumor growth in xenograft A549 tumor mice models^[1].
Diosbulbin B (16-64 mg/kg, i.g., daily for 12 days) induces liver injury in ICR mice^[2].